Novartis AG
NVS
NYSE
Last Updated: 1/23/2022 5:54:19 PM
High
Low
About Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.Novartis AG Company Details
CEO: Joseph Jimenez
Country: CH
Industry: Drug Manufacturers—General
Website: https://www.novartis.com
Exchange: New York Stock Exchange
IPO\Launch Date: 2001-09-05
Novartis AG Company Executive Details
Ms. Marie-France Tschudin
Pres of Novartis Pharmaceuticals
Dr. James E. Bradner M.D.
Pres of Novartis Institutes for Biomedical Research
Mr. Richard Saynor
Chief Executive Officer of Sandoz
Ms. Susanne Schaffert Ph.D.
Pres of Novartis Oncology
Mr. Robert Weltevreden
Head of Customer & Technology Solutions
Novartis AG Latest News
Novartis Hopes to Have Another COVID Therapy on the Way
Novartis and Molecular Partners reported positive results for COVID-19 candidate ensovibep.
Published on: 2022-01-23 02:28:00
Impact on Symbol / Company: NVS
View News
Vera: Biotech With 3 Mid-Stage Programs With Potential For Success
Vera: Biotech With 3 Mid-Stage Programs With Potential For Success
Published on: 2022-01-19 01:28:57
Impact on Symbol / Company: NVS
View News
Surface Oncology: If Novartis, GlaxoSmithKline And ARK See Promise, So Do I
Surface Oncology: If Novartis, GlaxoSmithKline And ARK See Promise, So Do I
Published on: 2022-01-18 08:00:00
Impact on Symbol / Company: NVS
View News
3 Top Biotech Stocks to Buy Right Now
Each of these companies possesses solid fundamentals and trades at reasonable valuations.
Published on: 2022-01-15 07:50:00
Impact on Symbol / Company: NVS
View News
7 Best Long-Term Stocks to Buy and Hold for the Next Decade
These seven long-term stocks are among the best picks for truly long-term investors looking for companies to hold for the next decade. The post 7 Best Long-Term Stocks to Buy and Hold for the Next Decade appeared first on InvestorPlace.
Published on: 2022-01-13 14:34:59
Impact on Symbol / Company: NVS
View News
Novartis CEO: We're moving toward filing Covid drug from Molecular Partners with FDA
Novartis CEO Vas Narasimhan sits down with CNBC's Meg Tirrell and the 'Squawk on the Street' team to discuss the company's latest Covid-19 treatment, which it licensed from Molecular Partners.
Published on: 2022-01-12 10:45:09
Impact on Symbol / Company: NVS
View News
Molecular (MOLN), Novartis Post Positive Data From COVID-19 Drug
Molecular (MOLN) and Novartis announce encouraging data from a phase II study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19. Shares of Molecular Partners gain on the same.
Published on: 2022-01-11 13:05:11
Impact on Symbol / Company: NVS
View News
Molecular Partners Stock Surges as Novartis Plans to License Covid-19 Drug
Novartis says it will license antiviral Covid-19 treatment ensovibep from Molecular Partners following positive trial results.
Published on: 2022-01-10 08:09:00
Impact on Symbol / Company: NVS
View News
Novartis To In-License COVID-19 Treatment From Molecular Partners, After Encouraging Mid-Stage Data
After getting positive trial data, Novartis AG (NYSE: NVS) said it would in-license a new drug developing with Molecular Partners AG (NASDAQ: MOLN) to treat COVID-19. Novartis will pay CHF 150 million to in-license ensovibep from Molecular Partners.
Published on: 2022-01-10 05:46:47
Impact on Symbol / Company: NVS
View News
Novartis (NVS) Partners With Alnylam for Liver-Targeted Therapies
Novartis (NVS) partners with Alnylam (ALNY) to collaborate on the discovery and the development of siRNA-based targeted therapy to restore functional liver cells.
Published on: 2022-01-07 18:23:06
Impact on Symbol / Company: NVS
View News
Buy Signals Sound For 14 Top January Dividends On Earth
Kiplinger "insights for investors" online, first published 91 "Top Dividend Stocks From Around The World" 7/13/20. Two Kiplinger articles provided this 105 Best Dividend Stocks on Earth list compiled 7/1/21.
Published on: 2022-01-07 16:33:30
Impact on Symbol / Company: NVS
View News
Novartis says U.S. court upholds Gilenya patent
Novartis AG said on Tuesday a U.S. court of appeals upheld the validity of a dosage regimen patent for its multiple sclerosis treatment Gilenya, allowing a permanent injunction against Chinese generic drugmaker HEC Pharma to stay in place until the patent expires in 2027.
Published on: 2022-01-04 01:44:00
Impact on Symbol / Company: NVS
View News
Grow your Money
We helps you in understanding the science behind growing the money, which will help you diversify your funds as per your requirements and helps in achieving your retirement goals, children education, investment in property, business or any smart looking startup ventures
Services we Offer
We offer several services including expert recommendations & suggestions on buying ETF, Mutual Funds, Bonds, Debt securities, Equities, Property invesments and several others
Live Market Data
We provide you live market data for your analysis, review and looking out for quick buying opportunities to help you